Conatus Pharmaceuticals Inc.
CNAT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.34 |
| Beta | - |
| Outstanding Shares | 33,170,000 |
Return
| Return on Equity | -57.36% |
|---|---|
| Return on Assets | -53.86% |
| Return on Invested Capital | -55.94% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Conatus Pharmaceuticals, Inc.
6 employees
CEO: Steven J. Mento
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor...